Eisai Develops New Drug for Mesothelioma
Eisai, and its subsidiary Morphotek, discovered and have developed an investigational monoclonal antibody amatuximab. This drug “has a high affinity and specificity for mesothelin, a protein which is overexpressed in people with malignant mesothelioma.” The European Commission has granted this antibody an orphan drug designation (ODD). This designation is for medicines developed for the diagnosis, …